MedPath

Cohort phase 2 study of hepatic arterial chemotherapy with cisplatin and 5-FU, and sorafenib in patients with advanced unresectable hepatocellular carcinoma

Phase 2
Recruiting
Conditions
unresectable advanced hepatocellular carcinoma
Registration Number
JPRN-UMIN000004022
Lead Sponsor
Kurume University, School of Medicine, Division of Gastroenterology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1) extrahepatic metastasis 2) pregnant woman 3) drug allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath